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The introduction of the broad-spectrum third-generation 
cephalosporins permitted the safe and effective treat- 
ment of serious infections caused by Gram-negative 
bacilli. In 1983, however, Knothe et al described clinical 
isolates of Klebsiellu spp. resistant to third-generation 
cepha1osporins.l This resistance was mediated by the p- 
lactamase enzyme SHV-2, the first extended-spectrum 
P-lactamase (ESBL).2 SHV-2 differed from the narrow- 
spectrum, chromosomally mediated SHV-1 (previously 
known to be present in Klebsiella) by a single amino 
acid substitution. Since then, numerous other p-lacta- 
mases have been described.3 Their presence on plasmids 
and transposons has permitted them to be transmitted 
easily to bacteria that did not originally possess them.4 
Outbreaks of bacteria possessing ESBLs now represent 
a substantial problem in many hospitals.5-y 
The usual risk factors for carriage of, or infection 
with, an ESBL-producing organism include residence 
in a nursing home, prolonged hospital stay, residence 
in an intensive care unit, urinary catheterization, prior 
receipt of ceftazidime or aztreonam, and other markers 
of poor health status.y It has been suggested that anti- 
biotic pressure and the presence of resistant genes favor 
the development of new ESBLS.~ 
Against this background, we were surprised to 
isolate an ESBL-producing Escherichia coli strain from 
a patient with none of the usual risk factors who pre- 
sented to the Emergency Department of our hospital in 
septic shock. 
A 50-year-old woman, a machine operator, pre- 
sented on 22 October 2000 with a 3-day history of fever, 
chills, rigors, and myalgia. There was a mild headache, 
but no cough, dysuria, diarrhea, or vomiting. 
Physical examination was remarkable for a blood 
pressure of 54/32 mmHg in the Emergency Department. 
No localizing signs were found. Investigations revealed 
the following: hemoglobin 10.6 g/dL, white cell count 
31.27 x lO”/L (polymorphs 95%, lymphocytes 2%, mono- 
cytes 3%), platelets 178x 10y/L, sodium 137 mmol/L, 
creatinine 51 p,mol/L, protein 52 g/L, albumin 27 g/L, 
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bilirubin 26 kmol/L, alkaline phosphatase 65 U/L, alanine 
aminotransferase 20 U/L, aspartate aminotransferase 
40 U/L, lactate dehydrogenase 479 U/L, creatinine kinase 
652 U/L (upper limit of normal range, 380), aldolase 15 
U/L (upper limit of normal range, 12). Urinalysis showed 
red blood cells l-2 per high power field (hpf), white blood 
cells 1-2/hpf, casts nil. 
A chest radiograph showed clear lung fields, and an 
electrocardiogram was normal. 
The patient was brought to the medical intensive 
care unit and resuscitated. Her blood pressure responded 
to fluids and dopamine. She was started on intravenous 
ciprofloxacin and crystalline penicillin, and switched to 
ceftazidime and clindamycin on the next day. 
Blood cultures yielded an ESBL-producing 
Escherichia coli strain sensitive to piperacillin-tazo- 
bactam, ciprofloxacin, gentamicin, and imipenem. An 
ESBL was detected using the double disk diffusion 
test.*OJ She was put on piperacillin-tazobactam, and 
completed a lo-day course of the drug before being sent 
home on ciprofloxacin. 
A search for a source of the bacteremia was 
unsuccessful, apart from a diverticulum of the ascending 
colon (shown on barium enema). A CT scan of the 
abdomen and pelvis was unremarkable. 
The recovery of an ESBL-producing E. coli strain 
from the blood cultures of a patient who presented from 
the community and who had none of the usual risk factors 
for colonization or infection with such an organism was 
surprising. 
ESBLs are derivatives of narrow-spectrum TEM-1 
or SHV-1 p-lactamases3 One or more amino acid sub- 
stitutions near the active site of the enzyme have led to 
remodeling, giving the enzyme increased affinity and 
hydrolytic activity for oxyimino substrates (cefotaxime, 
ceftazidime, ceftriaxone, aztreonam). These enzymes 
have been found in both Klebsiella spp. (usually 
Klebsiella pneumoniae) and E. coli.= 
We were surprised to isolate an ESBL-producing E. 
coli strain from this patient who was previously well, who 
had been living and working in the community, who had 
had no contact with sick persons, whose only antibiotic 
exposure had been a short course of amoxicillin several 
months earlier, and whose only contact with a hospital 
had been a 2-day stay for a dilation and curettage. 
We are not sure how the patient acquired the organ- 
ism. The prevalence of carriage of ESBL-producing 
organisms in community patients in Singapore is un- 
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known. Reports of community-acquired infections with 
ESBL-producing organisms are rare. Radice et al 
reported the isolation of an ESBL-producing Shigeflu 
sonnei strain from the stool sample of a 6-month-old 
girl.i2 The child had been hospitalized about 20 days 
previously for diarrhea, and had received a l-week course 
of gentamicin. Shigella infections are common in the 
area of residence of the child, but no resistant Shigella 
strains had been isolated from any other pediatric 
patients in their hospital that month.12 
It is possible that our patient acquired the organism 
(or another organism that carried an ESBL-coding 
plasmid) during a hospitalization 1 year before the 
current admission. This is an explanation that Radice et 
al also put forward for the surprising finding of com- 
munity-acquired ESBL-producing Shigella-acquisition 
of resistant enterobacteria and transference in vivo to 
(in their patient’s case) a freshly acquired Shigella 
strain.12 It should be pointed out that, in the case 
reported by Radice et al, the most recent hospitalization 
was 20 days prior to the one of interest, whereas in our 
patient’s case, the previous hospitalization was 1 year 
before. The role of the short course of amoxicillin that 
our patient received is uncertain, but it may have 
contributed to a milieu favoring the persistence of ESBL- 
producing organisms. Gastrointestinal colonization is 
usually present prior to infection with such organisms,9,1” 
and in this case must have persisted despite competition 
from community organisms. Perhaps a community survey 
of ESBL-producing organisms is indicated. 
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